Search results
Showing 7606 to 7620 of 8223 results
Space from Depression for treating adults with depression (MIB215)
This advice has been updated and replaced by NICE HealthTech guidance 675.
Discontinued Reference number: GID-TA11008
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
Improving supportive and palliative care for adults with cancer (CSG4)
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
NICE has retired this cancer service guideline because the recommendations are no longer being kept up to date and may no longer reflect best practice.Retired guidance is no longer being actively maintained. The guidance has no status, and the health and care system is not expected to follow it. Retired guidance is available as a PDF for reference only.
Discontinued Reference number: GID-PHG59
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
In development Reference number: GID-TA10858 Expected publication date: TBC
Sotagliflozin with insulin for treating type 1 diabetes (TA622)
NICE has withdrawn this guidance. This is because the company is no longer marketing sotagliflozin (Zynquista) and its marketing authorisation has been withdrawn.
In development Reference number: GID-TA11214 Expected publication date: TBC
In development Reference number: GID-TA11457 Expected publication date: TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)
This guidance has been updated and replaced by NICE technology appraisal guidance 1119.
Entrectinib for treating NTRK fusion-positive solid tumours (TA644)
This guidance has been updated and replaced by NICE technology appraisal guidance 1118. People already having entrectinib for treating neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumours through the Cancer Drugs Fund will be able to continue until they and their healthcare professional decide when best to stop.
Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (MTG72)
We have moved Medical technologies guidance 72 to become HealthTech guidance 642. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
This guidance has been updated and replaced by NICE technology appraisal guidance 1120.
Discontinued Reference number: GID-TA10452